scispace - formally typeset
M

Mark Pimentel

Researcher at Cedars-Sinai Medical Center

Publications -  366
Citations -  12985

Mark Pimentel is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Irritable bowel syndrome & Small intestinal bacterial overgrowth. The author has an hindex of 55, co-authored 327 publications receiving 10861 citations. Previous affiliations of Mark Pimentel include University of Calgary & University of California, Los Angeles.

Papers
More filters
Journal ArticleDOI

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

TL;DR: Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools.
Journal ArticleDOI

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

TL;DR: An improvement in irritable bowel syndrome symptoms with diarrhea and abdominal pain being statistically significant after Bonferroni correction is revealed.
Journal ArticleDOI

Normalization of Lactulose Breath Testing Correlates With Symptom Improvement in Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo-Controlled Study

TL;DR: Normalization of LBT with neomycin leads to a significant reduction in IBS symptoms, and the type of gas seen on LBT is also associated with IBS subgroup.
Journal ArticleDOI

The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome: A Randomized Trial

TL;DR: In this paper, a double-blind, randomized, placebo-controlled study was conducted to determine whether the nonabsorbed antibiotic rifaximin is more effective than placebo in reducing symptoms in adults with IBS.